BD Biosciences, a segment of medical technology major
Becton, Dickinson and Company
), entered a collaboration agreement with Wash.-based life
science research tools provider
NanoString Technologies, Inc.
) to develop a single cell isolation and analysis workflow.
ALPHATEC HLDGS (ATEC): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
NANOSTRING TECH (NSTG): Free Stock Analysis
STRAUMANN (SAUHF): Get Free Report
To read this article on Zacks.com click here.
Under the agreement, both the companies will take the help of
NanoString's nCounter Analysis System (including the nCounter
Single Cell Assay) and BDX's BD Flow Cytometry cell sorter
product line (emphasizing the new BD FACSJazz Cell Sorting
System) to develop the combined workflow.
NanoString Technologies' nCounter Analysis System is a
multi-application digital detection and counting system with a
highly automated and simple workflow. Its Single Cell Gene
Expression application helps researchers adopt a highly flexible
and sensitive approach to identify variations in cell-to-cell
gene expression profiles. The application helps detection up to
800 genes in a single tube.
On the other hand, the BD FACSJazz Cell Sorting System is capable
of identifying, characterizing and isolating single or multiple
cells from complex or rare cell populations and depositing them
in 96 and 384 well plates to provide rapid cell isolation,
tracking and identification.
The combined workflow will provide single cell gene expression
analysis for oncology, immunology and stem cell research. The
collaboration agreement also includes the development of
materials documenting the workflow protocol, as well as
undertaking meetings and webinars to educate scientists about the
single cell workflow.
Recently, BD Diagnostics, another segment of Becton, Dickinson
and Company, has launched the BD ProbeTec Trichomonas vaginalis
Qx Amplified DNA Assay used for the detection of T. vaginalis DNA
in endocervical and vaginal samples as well as neat urine
specimens to aid in the diagnosis of trichomoniasis on the BD
Viper System with XTR Technology.
The DNA assay has been cleared by the U.S. Food and Drug
Administration (FDA). It is designed for use with the BD Viper
System. It reduces human intervention and associated variables as
well as improves speed to results compared to wet mount
microscopy and culture.
Becton, Dickinson and Company reported a marginal 1.3% rise in
third quarter fiscal 2013 adjusted earnings per share from
continuing operations to $1.54, beating the Zacks Consensus
Estimate of $1.47. Revenues went up 3.6% (up 5.1% in constant
currency or CER) to $2,052.7 million, which were marginally ahead
of the Zacks Consensus Estimate of $2,050 million.
Becton, Dickinson and Company expects lower sales growth for
fiscal 2013 in the range of 3.5% to 4% (5.0% at CER) compared
with the earlier projection of 4.5% to 5.0%. BDX continues to
expect reported earnings per share from continuing operations for
fiscal 2013 in the band of $5.72−$5.75. The projection implies a
year-over-year rise of 6.5%−7.0% (8.5%−9.0% at CER) for fiscal
2013 or 11.0%−11.5% after accounting for the medical device tax
implemented in Jan 2013.
Currently, BDX carries a Zacks Rank #3 (Hold). Other medical
stocks that are worth considering include
STRAUMANN HLD N AKT
) with a Zacks Rank #1 (Strong Buy), and
Alphatec Holdings, Inc.
) with a Zacks Rank #2 (Buy).